Table of Contents Author Guidelines Submit a Manuscript
Spectroscopy: An International Journal
Volume 27 (2012), Article ID 913913, 10 pages
http://dx.doi.org/10.1155/2012/913913

Spectrofluorometric Determination of Certain Antihyperlipidemic Agents in Bulk and Pharmaceutical Preparations

1Pharmaceutical Chemistry Department, Faculty of Pharmacy, Cairo University, Cairo 11562, Egypt
2National Organization for Drug Control and Research (NODCAR), P.O. Box 29, Giza 35521, Egypt

Copyright © 2012 Ramzia I. El-Bagary et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. P. Beringer, Remington: The Science and Practice of Pharmacy, Lippincott Williams & Wilkins, New York, NY, USA, 21st edition, 2006.
  2. H. Lennernäs and G. Fager, “Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences,” Clinical Pharmacokinetics, vol. 32, no. 5, pp. 403–425, 1997. View at Google Scholar · View at Scopus
  3. E. Leitersdorf, “Selective cholesterol absorption inhibition: a novel strategy in lipid-lowering management,” International Journal of Clinical Practice, vol. 56, no. 2, pp. 116–119, 2002. View at Google Scholar · View at Scopus
  4. M. V. Heek, C. Farley, D. S. Compton, L. Hoos, and H. R. Davis, “Ezetimibe selectively inhibits intestinal cholesterol absorption in rodents in the presence and absence of exocrine pancreatic function,” British Journal of Pharmacology, vol. 134, no. 2, pp. 409–417, 2001. View at Google Scholar · View at Scopus
  5. T. R. Kumar, N. R. Shitut, P. K. Kumar et al., “Determination of rosuvastatin in rat plasma by HPLC: validation and its application to pharmacokinetic studies,” Biomedical Chromatography, vol. 20, no. 9, pp. 881–887, 2006. View at Publisher · View at Google Scholar · View at Scopus
  6. S. Vittal, T. R. Kumar, N. R. Shitut, M. C. Vinu, R. Muliangi, and N. R. Srinivas, “Simultaneous quantitation of rosuvastatin and gemfibrozil in human plasma by high-performance liquid chromatography and its application to a pharmacokinetic study,” Biomedical Chromatography, vol. 20, no. 11, pp. 1252–1259, 2006. View at Publisher · View at Google Scholar · View at Scopus
  7. T. N. Mehta, A. K. Patel, G. M. Kulkarini, and G. Suubbaiah, “Determination of rosuvastatin in the presence of its degradation products by a stability-indicating LC method,” Journal of AOAC International, vol. 88, no. 4, pp. 1142–1147, 2005. View at Google Scholar · View at Scopus
  8. B. Uyar, M. Celebier, and S. Altinoz, “Spectrophotometric determination of rosuvastatin calcium in tablets,” Pharmazie, vol. 62, no. 6, pp. 411–413, 2007. View at Publisher · View at Google Scholar · View at Scopus
  9. R. T. Sane, S. S. Kamat, S. N. Menon, S. R. Inamdar, and M. R. Mote, “Determination of rosuvastatin calcium in its bulk drug and pharmaceutical preparations by high-performance thin-layer chromatography,” Journal of Planar Chromatography, vol. 18, no. 103, pp. 194–198, 2005. View at Publisher · View at Google Scholar · View at Scopus
  10. R. Sistla, V. S. S. K. Tata, Y. V. Kashyap, D. Chandrasekar, and P. V. Diwan, “Development and validation of a reversed-phase HPLC method for the determination of ezetimibe in pharmaceutical dosage forms,” Journal of Pharmaceutical and Biomedical Analysis, vol. 39, no. 3-4, pp. 517–522, 2005. View at Publisher · View at Google Scholar · View at Scopus
  11. S. K. Akmar, L. Kothapalli, A. Thomas, S. Jangam, and A. Deshpande, “Reverse phase high performance liquid chromatography method for estimation of ezetimibe in bulk and pharmaceutical formulations,” Indian Journal of Pharmaceutical Sciences, vol. 69, no. 5, pp. 695–697, 2007. View at Google Scholar · View at Scopus
  12. S. Singh, B. Singh, R. Bahuguna, L. Wadhwa, and R. Saxena, “Stress degradation studies on ezetimibe and development of a validated stability-indicating HPLC assay,” Journal of Pharmaceutical and Biomedical Analysis, vol. 41, no. 3, pp. 1037–1040, 2006. View at Publisher · View at Google Scholar · View at Scopus
  13. A. S. Doshi, P. K. Kachhadia, and H. S. Joshi, “Validation of a stability-indicating LC method for assay of ezetimibe in tablets and for determination of content uniformity,” Chromatographia, vol. 67, no. 1-2, pp. 137–142, 2008. View at Publisher · View at Google Scholar · View at Scopus
  14. S. Oswald, E. Scheuch, I. Cascorbi, and W. Siegmund, “A LC-MS/MS method to quantify the novel cholesterol lowering drug ezetimibe in human serum, urine and feces in healthy subjects genotyped for SLCO1B1,” Journal of Chromatography B, vol. 830, no. 1, pp. 143–150, 2006. View at Publisher · View at Google Scholar · View at Scopus
  15. S. Li, G. Liu, J. Jia, X. Li, and C. Yu, “Liquid chromatography-negative ion electrospray tandem mass spectrometry method for the quantification of ezetimibe in human plasma,” Journal of Pharmaceutical and Biomedical Analysis, vol. 40, no. 4, pp. 987–992, 2006. View at Publisher · View at Google Scholar · View at Scopus
  16. N. Jain, R. Jain, H. Swami, S. Pandey, and D. K. Jain, “Spectrophotometric method for simultaneous estimation of simvastatin and ezetimibe in bulk drug and its combined dosage form,” International Journal of Pharmacy and Pharmaceutical Sciences, no. 1, pp. 170–175, 2009. View at Google Scholar · View at Scopus
  17. B. G. Chaudhari, N. Patel, P. B. Shah, L. J. Patel, and V. P. Patel, “Stability-indicating reversed-phase liquid chromatographic method for simultaneous determination of atorvastatin and ezetimibe from their combination drug products,” Journal of AOAC International, vol. 90, no. 6, pp. 1539–1546, 2007. View at Google Scholar · View at Scopus
  18. B. G. Chaudhari, N. M. Patel, and P. B. Shah, “Stability-indicating reversed-phase liquid chromatographic method for simultaneous determination of simvastatin and ezetimibe from their combination drug products,” Journal of AOAC International, vol. 90, no. 5, pp. 1242–1249, 2007. View at Google Scholar · View at Scopus
  19. H. J. Panchal, B. N. Suhagia, M. M. Patel, and B. H. Patel, “Estimation of pravastatin calcium in tablet dosage forms by column liquid chromatography and ultraviolet spectrophotometry,” Journal of AOAC International, vol. 92, no. 1, pp. 158–164, 2009. View at Google Scholar · View at Scopus
  20. S. N. Kumar and J. Baghyalakshmi, “Determination and quantification of pitavastatin calcium in tablet dosage formulation by HPTLC method,” Analytical Letters, vol. 40, no. 14, pp. 2625–2632, 2007. View at Publisher · View at Google Scholar · View at Scopus
  21. J. H. Shen-Tu, X. Xu, J. Liu et al., “Determination of pitavastatin in human plasma by LC-MS-MS,” Chromatographia, vol. 69, no. 9-10, pp. 1041–1047, 2009. View at Publisher · View at Google Scholar · View at Scopus
  22. B. Di, M. X. Su, F. Yu et al., “Solid-phase extraction and liquid chromatography/tandem mass spectrometry assay for the determination of pitavastatin in human plasma and urine for application to Phase I clinical pharmacokinetic studies,” Journal of Chromatography B, vol. 868, no. 1-2, pp. 95–101, 2008. View at Publisher · View at Google Scholar · View at Scopus
  23. L. Tian, Y. Huang, Y. Jia, L. Hua, and Y. Li, “Development and validation of a liquid chromatography-tandem mass spectrometric assay for pitavastatin and its lactone in human plasma and urine,” Journal of Chromatography B, vol. 865, no. 1-2, pp. 127–132, 2008. View at Publisher · View at Google Scholar · View at Scopus
  24. J. W. Deng, K. B. Kim, I. S. Song et al., “Determination of two HMG-CoA reductase inhibitors, pravastatin and pitavastatin, in plasma samples using liquid chromatography-tandem mass spectrometry for pharmaceutical study,” Biomedical Chromatography, vol. 22, no. 2, pp. 131–135, 2008. View at Publisher · View at Google Scholar · View at Scopus
  25. I. A. Shehata, S. M. EL-Ashry, M. A. EL-Sherbeny, D. T. EL-Sherbeny, and F. Belal, “Fluorimetric determination of some thioxanthene derivatives in dosage forms and biological fluids,” Journal of Pharmaceutical and Biomedical Analysis, vol. 22, no. 5, pp. 729–737, 2000. View at Publisher · View at Google Scholar · View at Scopus
  26. M. Rizk, F. Belal, F. Ibrahim, S. Ahmed, and N. El-Enany, “Spectrofluorimetric analysis of certain 4-quinolone in pharmaceuticals and biological fluids,” Pharmaceutica Acta Helvetiae, vol. 74, no. 4, pp. 371–377, 2000. View at Publisher · View at Google Scholar · View at Scopus
  27. F. Belal, F. Ibrahim, S. M. Hassan, and F. A. Aly, “Spectrofluorimetric determination of some pharmaceutically important thioxanthene derivatives,” Analytica Chimica Acta, vol. 255, no. 1, pp. 103–106, 1991. View at Publisher · View at Google Scholar · View at Scopus
  28. L. I. Bebawy, S. S. Abbas, L. A. Fattah, and H. H. Refaat, “Application of first-derivative, ratio derivative spectrophotometry, TLC-densitometry and spectrofluorimetry for the simultaneous determination of telmisartan and hydrochlorothiazide in pharmaceutical dosage forms and plasma,” Farmaco, vol. 60, no. 10, pp. 859–867, 2005. View at Publisher · View at Google Scholar · View at Scopus